Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotonib and dasatinib are not considered appropriate treatment options.

This is written in the approval document.

Reimbursement

CDS

Citation

Bosutinib Monotherapy, 2021, version number 4, NCCP National SACT Regimen, viewed 26/03/2026, https://healthservice.hse.ie/documents/6943/224_v4_Bosutinib_Monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	BCR::ABL1	Chronic Myelogenous Leukemia	Bosutinib
HSE (1)	BCR::ABL1	Chronic Myeloid Leukemia, BCR-ABL1+	Bosutinib